Skip to main content

A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.

Publication ,  Journal Article
Choi, BD; Pastan, I; Bigner, DD; Sampson, JH
Published in: Oncoimmunology
April 1, 2013

Bispecific T-cell engagers (BiTEs) may break multiple barriers that currently limit the use of immunotherapy in glioblastoma patients. We have recently described a novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, that exerts potent antineoplastic effects against established invasive tumors of the brain.

Duke Scholars

Published In

Oncoimmunology

DOI

ISSN

2162-4011

Publication Date

April 1, 2013

Volume

2

Issue

4

Start / End Page

e23639

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
  • 1112 Oncology and Carcinogenesis
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Choi, B. D., Pastan, I., Bigner, D. D., & Sampson, J. H. (2013). A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology, 2(4), e23639. https://doi.org/10.4161/onci.23639
Choi, Bryan D., Ira Pastan, Darell D. Bigner, and John H. Sampson. “A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.Oncoimmunology 2, no. 4 (April 1, 2013): e23639. https://doi.org/10.4161/onci.23639.
Choi, Bryan D., et al. “A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.Oncoimmunology, vol. 2, no. 4, Apr. 2013, p. e23639. Pubmed, doi:10.4161/onci.23639.

Published In

Oncoimmunology

DOI

ISSN

2162-4011

Publication Date

April 1, 2013

Volume

2

Issue

4

Start / End Page

e23639

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
  • 1112 Oncology and Carcinogenesis
  • 1107 Immunology